Metabolic syndrome as a risk factor for neurological disorders

Cellular and Molecular Life Sciences

Volumn 69, Issue 5, 2012, Pages 741-762

  Farooqui, Akhlaq A ^a   Farooqui, Tahira ^a   Panza, Francesco ^b   Frisardi, Vincenza ^b  

^a OHIO STATE UNIVERSITY   (United States)

^b CASA SOLLIEVO DELLA SOFFERENZA HOSPITAL   (Italy)

Author keywords

Alzheimer's disease; Depression; Hypertension; Inflammation; Insulin; Insulin resistance; Leptin; Metabolic syndrome; Oxidative stress; Stroke

Indexed keywords

4 HYDROXYNONENAL; AMYLOID BETA PROTEIN; BETA SECRETASE; CANNABINOID 1 RECEPTOR; CHOLECYSTOKININ; DIACYLGLYCEROL; DOCOSAHEXAENOIC ACID; ENDOCANNABINOID; GLUCOSE; ICOSAPENTAENOIC ACID; INSULIN; INSULIN RECEPTOR SUBSTRATE 2; LEPTIN; LEUKOTRIENE; LIVER X RECEPTOR; MAMMALIAN TARGET OF RAPAMYCIN COMPLEX 1; MAMMALIAN TARGET OF RAPAMYCIN COMPLEX 2; NITRIC OXIDE; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHOLIPID; PROSTAGLANDIN; SPHINGOLIPID; THROMBOCYTE ACTIVATING FACTOR; THROMBOXANE;

ALZHEIMER DISEASE; ARCUATE NUCLEUS; BRAIN ISCHEMIA; CARBOHYDRATE METABOLISM; CARDIOVASCULAR DISEASE; DEPRESSION; DISEASE ASSOCIATION; DYSLIPIDEMIA; FATTY ACID TRANSPORT; GLUCOSE HOMEOSTASIS; HUMAN; HYPERGLYCEMIA; HYPERTENSION; HYPOTHALAMUS; HYPOTHALAMUS HYPOPHYSIS ADRENAL SYSTEM; INSULIN RESISTANCE; LIPID METABOLISM; LIPID OXIDATION; LIPID STORAGE; METABOLIC SYNDROME X; NEUROLOGIC DISEASE; NEUROPROTECTION; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; OXIDATIVE STRESS; PARKINSON DISEASE; PATHOGENESIS; REVIEW; RISK FACTOR; SIGNAL TRANSDUCTION;

ADIPOKINES; CERAMIDES; ENDOCANNABINOIDS; HUMANS; INSULIN; INSULIN RESISTANCE; LEPTIN; LIPID METABOLISM; METABOLIC SYNDROME X; NERVOUS SYSTEM DISEASES; RISK FACTORS;

EID: 84857058397     PISSN: 1420682X     EISSN: 14209071     Source Type: Journal    
DOI: 10.1007/s00018-011-0840-1     Document Type: Review

References (191)

1. Flegal KM, Carroll MD, Ogden CL, Curtin R (2010) Prevalence and trends in obesity among US adults, 1999-2008. JAMA 303:235-241
2. Reaven GM, Laws A (1999) Insulin resistance the metabolic syndrome X. Humana Press Totowa, NJ
3. Grundy SM, Hansen B, Smith SC Jr, Cleeman JI, Kahn RA, American Heart Association (2004) Clinical management of metabolic syndrome report of the American Heart Association/National Heart, Lung, and Blood Institute/American Diabetes Association conference on scientific issues related to management. Circulation 109:551-556 (Pubitemid 38168522)
4. Groenendijk M, Cantor RM, Blom NH, Rotter JI, de Bruin TW, Dallinga-Thie GM (1999) Association of plasma lipids and apolipoproteins with the insulin response element in the apoCIII promoter region in familial combined hyperlipidemia. J Lipid Res 40:1036-1044 (Pubitemid 29287874)
5. Mooradian AD, Haas MJ, Wong NC (2004) Transcriptional control of apolipoprotein A-I gene expression in diabetes. Diabetes 53:513-520 (Pubitemid 38270617)
6. Tripathy D, Mohanty P, Dhindsa S, Syed T, Ghanim H, Aljada A, Dandona P (2003) Elevation of free fatty acids induces inflammation and impairs vascular reactivity in healthy subjects. Diabetes 52(12):2882-2887 (Pubitemid 37466856)
7. Roden M, Perseghin G, Petersen KF, Hwang JH, Cline GW, Gerow K, Rothman DL, Shulman GI (1996) The roles of insulin and glucagon in the regulation of hepatic glycogen synthesis and turnover in humans. J Clin Invest 97:642-648 (Pubitemid 26057081)
8. Shulman GI (2000) Cellular mechanisms of insulin resistance. J Clin Invest 106:171-176 (Pubitemid 30483118)
9. Greenberg AS, Obin MS (2006) Obesity and the role of adipose tissue in inflammation and metabolism. Am J Clin Nutr 83:S461-S465
10. Ahima RS, Osei SY (2008) Adipokines in obesity. Front Horm Res 36:182-197
11. Uranga RM, Bruce-Keller AJ, Morrison CD, Fernandez-Kim SO, Ebenezer PJ, Zhang L, Dasuri K, Keller JN (2010) Intersection between metabolic dysfunction, high fat diet consumption, and brain aging. J Neurochem 114:344-361
12. Moller DE, Kaufman KD (2005) Metabolic syndrome: a clinical and molecular perspective. Annu Rev Med 56:45-62 (Pubitemid 40299773)
13. Wang S, Ma A, Song S, Quan Q, Zhao X, Zheng X (2008) Fasting serum free fatty acid composition, waist/hip ratio and insulin activity in essential hypertensive patients. Hypertens Res 31:623-632 (Pubitemid 351772852)
14. Van Gaal LF, Mertens IL, De Block CE (2006) Mechanisms linking obesity with cardiovascular disease. Nature 444:875-880 (Pubitemid 46028447)
15. Lteif AA, Han K, Mather KJ (2005) Obesity, insulin resistance, and the metabolic syndrome: determinants of endothelial dysfunction in whites and blacks. Circulation 112:32-38 (Pubitemid 40962566)
16. Steinberg HO, Chaker H, Leaming R, Johnson A, Brechtel G, Baron AD (1996) Obesity/insulin resistance is associated with endothelial dysfunction: implications for the syndrome of insulin resistance. J Clin Invest 97:2601-2610
17. Rutter MK, Meigs JB, Sullivan LM, D'Agostino RB Sr, Wilson PW (2004) C-reactive protein, the metabolic syndrome, and prediction of cardiovascular events in the Framingham Offspring Study. Circulation 110:380-385 (Pubitemid 38993845)
18. Aizawa Y, Watanabe H, Ramadan MM, Usuda Y, Watanabe T, Sasaki S (2007) Clustering trend of components of metabolic syndrome. Int J Cardiol 121:117-118 (Pubitemid 47287778)
19. Dhindsa S, Tripathy D, Mohanty P, Ghanim H, Syed T, Aljada A, Dandona P (2004) Differential effects of glucose and alcohol on reactive oxygen species generation and intranuclear nuclear factorkappaB in mononuclear cells. Metabolism 53:330-334 (Pubitemid 38684693)
20. Yu YH, Ginsberg HN (2005) Adipocyte signaling and lipid homeostasis: sequelae of insulin-resistant adipose tissue. Circ Res 96:1042-1052 (Pubitemid 40791376)
21. Friedman JM (2004) Modern science versus the stigma of obesity. Nat Med 10:563-569 (Pubitemid 38796839)
22. Trayhurn P, Hoggard N, Mercer JG, Rayner DV (1999) Leptin: fundamental aspects. Int J Obes Relat Metab Disord 23(Suppl 1):22-28 (Pubitemid 29101372)
23. Shimabukuro M, Koyama K, Chen G, Wang M-Y, Trieu F, Lee Y, Newgard CB, Unger RH (1997) Direct antidiabetic effect of leptin through triglyceride depletion of tissues. Proc Natl Acad Sci USA 94:4637-4641 (Pubitemid 27194295)
24. Flier JS (1998) What's in a name? In search of leptin's physiologic role. J Clin Endocrinol Metab 83:1407-1413 (Pubitemid 28500994)
25. Roberts CK, Barnard RJ, Sindhu RK, Jurczak M, Ehdaie A, Vaziri ND (2006) Oxidative stress and dysregulation of NAD(P)H oxidase and antioxidant enzymes in dietinduced metabolic syndrome. Metabolism 55:928-934 (Pubitemid 43902895)
26. Iyer A, Fairlie DP, Prins JB, Hammock BD, Brown L (2010) Inflammatory lipid mediators in adipocyte function and obesity. Nat Rev Endocrinol 6:71-82
27. Frisardi V, Solfrizzi V, Seripa D, Capurso C, Santamato A, Sancarlo D, Vendemiale G, Pilotto A, Panza F (2010) Metabolic-cognitive syndrome: a cross-talk between metabolic syndrome and Alzheimer's disease. Ageing Res Rev 9:399-417
28. Oxenkrug GF (2010) Metabolic syndrome, age-associated neuroendocrine disorders, and dysregulation of tryptophankynurenine metabolism. Ann N Y Acad Sci 1199:1-14
29. Luchsinger JA, Gustafson DR (2009) Adiposity, type 2 diabetes, and Alzheimer's disease. J Alzheimers Dis 16:693-704
30. Frisardi V, Solfrizzi V, Capurso C, Imbimbo BP, Vendemiale G, Seripa D, Pilotto A, Panza F (2010) Is insulin resistant brain state a central feature of the metabolic-cognitive syndrome? J Alzheimers Dis 21:57-63
31. Delzenne NM, Cani PD, Neyrinck AM (2007) Modulation of glucagon-like peptide1 and energy metabolism by inulin and oligofructose: experimental data. J Nutr 137(11 Suppl):2547S-2551S (Pubitemid 350058733)
32. Burcelin R, Cani PD, Knauf C (2007) Glucagon-like peptide-1 and energy homeostasis. J Nutr 137(11 Suppl):2534S-2538S (Pubitemid 350058731)
33. Flier JS (2004) Obesity wars: molecular progress confronts an expanding epidemic. Cell 116:337-350 (Pubitemid 38167322)
34. Seeley RJ, York DA (2005) Fuel sensing and the central nervous system (CNS): implications for the regulation of energy balance and the treatment for obesity. Obes Rev 6:259-265 (Pubitemid 41032801)
35. Strader AD, Woods SC (2005) Gastrointestinal hormones and food intake. Gastroenterology 128(1):175-191 (Pubitemid 40039969)
36. Perez-Tilve D, Stern JE, Tschöp M (2006) The brain and the metabolic syndrome: not a wireless connection. Endocrinology 147:1136-1139 (Pubitemid 43244344)
37. Zsombok A, Smith BN (2009) Plasticity of central autonomic neural circuits in diabetes. Biochim Biophys Acta 1792:423-431
38. Pocai A, Obici S, Schwartz GJ, Rossetti L (2005) A brain-liver circuit regulates glucose homeostasis. Cell Metab 1:53-61 (Pubitemid 43960581)
39. Song CK, Jackson RM, Harris RB, Richard D, Bartness TJ (2005) Melanocortin-4 receptor mRNA is expressed in sympathetic nervous system outflow neurons to white adipose tissue. Am J Physiol Regul Integr Comp Physiol 289:R1467-R1476 (Pubitemid 41507413)
40. Penicaud L, Leloup C, Fioramonti X, Lorsignol A, Benani A (2006) Brain glucose sensing: a subtle mechanism. Curr Opin Clin Nutr Metab Care 9:458-462 (Pubitemid 44097818)
41. Lam TK, Schwartz GJ, Rossetti L (2005) Hypothalamic sensing of fatty acids. Nat Neurosci 8(5):579-584 (Pubitemid 40594197)
42. Niijima A (1985) Blood glucose levels modulate efferent activity in the vagal supply to the rat liver. J Physiol 364:105-112 (Pubitemid 15067202)
43. Shimazu T, Fukuda A, Ban T (1966) Reciprocal influences of the ventromedial and lateral hypothalamic nuclei on blood glucose level and liver glycogen content. Nature 210:1178-1179
44. Pocai A, Lam TK, Gutierrez-Juarez R, Obici S, Schwartz GJ, Bryan J, Aguilar-Bryan L, Rossetti L (2005) Hypothalamic K(ATP) channels control hepatic glucose production. Nature 434:1026-1031 (Pubitemid 40586051)
45. Hill JM, Lesniak MA, Pert CB, Roth J (1986) Autoradiographic localization of insulin receptors in rat brain: prominence in olfactory and limbic areas. Neuroscience 17:1127-1138 (Pubitemid 16080101)
46. de la Monte SM, Wands JR (2008) Alzheimer's disease is type 3 diabetes-evidence reviewed. J Diabetes Sci Technol 2:1101-1113
47. Freude S, Leeser U, Muller M, Hettich MM, Udelhoven M, Schilbach K, Tobe K, Kadowaki T, Kohler C, Schroder H, Krone W, Bruning JC, Schubert M (2008) IRS-2 branch of IGF-1 receptor signaling is essential for appropriate timing of myelination. J Neurochem 107:907-917
48. D'Ercole AJ, Ye P, Calikoglu AS, Gutierrez-Ospina G (1996) The role of the insulin-like growth factors in the central nervous system. Mol Neurobiol 13:227-255 (Pubitemid 126715878)
49. Martin DE, Hall MN (2005) The expanding TOR signaling network. Curr Opin Cell Biol 17(2):158-166 (Pubitemid 40380939)
50. Rui L (2007) A link between protein translation and body weight. J Clin Invest 117:310-313 (Pubitemid 46203959)
51. Jacinto E, Loewith R, Schmidt A, Lin S, Ruegg MA, Hall A, Hall MN (2004) Mammalian TOR complex 2 controls the actin cytoskeleton and is rapamycin insensitive. Nat Cell Biol 6:1122-1128 (Pubitemid 39468014)
52. Fraenkel M, Ketzinel-Gilad M, Ariav Y, Pappo O, Karaca M, Castel J, Berthault MF, Magnan C, Cerasi E, Kaiser N, Leibowitz G (2008) mTOR inhibition by rapamycin prevents beta-cell adaptation to hyperglycemia and exacerbates the metabolic state in type 2 diabetes. Diabetes 57:945-957
53. Baskin DG, Figlewicz Lattermann D, Seeley RJ, Woods SC, Porte D Jr, Schwartz MW (1999) Insulin and leptin: dual adiposity signals to the brain for the regulation of food intake and body weight. Brain Res 848:114-123 (Pubitemid 30001660)
54. Hadari YR, Tzahar E, Nadiv O, Rothenberg P, Roberts CT Jr, LeRoith D, Yarden Y, Zick Y (1992) Insulin and insulinomimetic agents induce activation of phosphatidylinositol 30-kinase upon its association with pp185 (IRS-1) in intact rat livers. J Biol Chem 267:17483-17486
55. Tartaglia LA (1997) The leptin receptor. J Biol Chem 272:6093-6096 (Pubitemid 27118072)
56. Koch CA, Anderson D, Moran MF, Ellis C, Pawson T (1991) SH2 and SH3 domains: elements that control interactions of cytoplasmic signaling proteins. Science 252:668-674 (Pubitemid 21916987)
57. Davis JF, Choi DL, Benoit SC (2010) Insulin, leptin and reward. Trends Endocrinol Metab 21:68-74
58. Myers MG Jr (2004) Leptin receptor signaling and the regulation of mammalian physiology. Recent Prog Horm Res 59:287-304
59. Xu AW, Kaelin CB, Takeda K, Akira S, Schwartz MW, Barsh GS (2005) PI3K integrates the action of insulin and leptin on hypothalamic neurons. J Clin Invest 115:951-958 (Pubitemid 40489399)
60. Morrison CD, Morton GJ, Niswender KD, Gelling RW, Schwartz MW (2005) Leptin inhibits hypothalamic Npy and Agrp gene expression via a mechanism that requires phosphatidylinositol 3-OH-kinase signaling. Am J Physiol Endocrinol Metab 289:E1051-E1057 (Pubitemid 43772054)
61. Mirshamsi S, Laidlaw HA, Ning K, Anderson E, Burgess LA, Gray A, Sutherland C, Ashford ML (2004) Leptin and insulin stimulation of signalling pathways in arcuate nucleus neurones: PI3K dependent actin reorganization and KATP channel activation. BMC Neurosci 5:54
62. Kim MS, Pak YK, Jang PG, Namkoong C, Choi YS, Won JC, Kim KS, Kim SW, Kim HS, Park JY, Kim YB, Lee KU (2006) Role of hypothalamic Foxo1 in the regulation of food intake and energy homeostasis. Nat Neurosci 9:901-906 (Pubitemid 43980504)
63. Morton GJ, Blevins JE, Kim F, Matsen M, Figlewicz DP (2009) The action of leptin in the ventral tegmental area to decrease food intake is dependent on Jak-2 signaling. Am J Physiol Endocrinol Metab 297:E202-E210
64. Farooqui AA (2011) Lipid mediators and their metabolism in the brain. Springer, New York
65. Riccardi G, Giacco R, Rivellese AA (2004) Dietary fat, insulin sensitivity and the metabolic syndrome. Clin Nutr 23:447-456 (Pubitemid 39107022)
66. Storlien LH, Kraegen EW, Chisholm DJ, Ford GL, Bruce DG, Pascoe WS (1987) Fish oil prevents insulin resistance induced by high-fat feeding in rats. Science 237:885-888 (Pubitemid 17128276)
67. Glauser DA, Schlegel W (2007) The emerging role of FOXO transcription factors in pancreatic beta cells. J Endocrinol 193:195-207
68. Kitamura T, Nakae J, Kitamura Y, Kido Y, Biggs WH 3rd, Wright CV, White MF, Arden KC, Accili D (2002) The forkhead transcription factor Foxo1 links insulin signaling to Pdx1 regulation of pancreatic beta cell growth. J Clin Invest 110:1839-1847 (Pubitemid 36076491)
69. Szanto I, Kahn CR (2000) Selective interaction between leptin and insulin signaling pathways in a hepatic cell line. Proc Natl Acad Sci USA 97:2355-2360 (Pubitemid 30134073)
70. Portois L, Hacquebard M, Malaisse WJ, Carpentier YA (2009) The metabolic syndrome of omega3-depleted rats. III. Brain phospholipids. Int J Mol Med 24:269-278
71. Edidin M (2003) The state of lipid rafts: from model membranes to cells. Annu Rev Biophys Biomol Struct 32:257-283 (Pubitemid 37056230)
72. Yaqoob P, Shaikh SR (2010) The nutritional and clinical significance of lipid rafts. Curr Opin Clin Nutr Metab Care 13:156-166
73. Plata-Salaman CR (1991) Insulin in the cerebrospinal fluid. Neurosci Biobehav Rev 15:243-258
74. Unger J, McNeill TH, Moxley RT, White M, Moss A, Livingston JN (1989) Distribution of insulin receptor-like immunoreactivity in the rat forebrain. Neuroscience 31:143-157 (Pubitemid 19209704)
75. de la Monte SM, Wands JR (2005) Review of insulin and insulin-like growth factor expression, signaling, and malfunction in the central nervous system: relevance to Alzheimer's disease. J Alzheimers Dis 7:45-61 (Pubitemid 40387184)
76. Frisardi V, Panza F, Seripa D, Imbimbo BP, Vendemiale G, Pilotto A, Solfrizzi V (2010) Nutraceutical properties of Mediterranean diet and cognitive decline: possible underlying mechanisms. J Alzheimers Dis 22:715-740
77. Farooqui AA (2009) Effect of fish oil on human brain. Springer, New York
78. Urakawa H, Katsuki A, Sumida Y, Gabazza EC, Murashima S, Morioka K, Maruyama N, Kitagawa N, Tanaka T, Hori Y, Nakatani K, Yano Y, Adachi Y (2003) Oxidative stress is associated with adiposity and insulin resistance in men. J Clin Endocrinol Metab 88:4673-4676 (Pubitemid 37357510)
79. Haffner SM (2006) The metabolic syndrome: inflammation, diabetes mellitus, and cardiovascular disease. Am J Cardiol 97:3A-11A (Pubitemid 43139714)
80. Evans JL, Goldfine ID, Maddux BA, Grodsky GM (2002) Oxidative stress and stress-activated signaling pathways: a unifying hypothesis of type 2 diabetes. Endocr Rev 23:599-622 (Pubitemid 35191625)
81. Muoio DM, Newgard CB (2006) Obesity-related derangements in metabolic regulation. Annu Rev Biochem 75:367-401 (Pubitemid 44118037)
82. Dimopoulos N, Watson M, Sakamoto K, Hundal HS (2006) Differential effects of palmitate and palmitoleate on insulin action and glucose utilization in rat L6 skeletal muscle cells. Biochem J 399:473-481 (Pubitemid 44672638)
83. Hajduch E, Litherland GJ, Hundal HS (2001) Protein kinase B: a key regulator of glucose transport? FEBS Lett 492:199-203 (Pubitemid 32217828)
84. Merrill AH Jr (2002) De novo sphingolipid biosynthesis: a necessary, but dangerous, pathway. J Biol Chem 277:25843-25846 (Pubitemid 34967059)
85. Holland WL, Brozinick JT, Wang LP, Hawkins ED, Sargent KM, Liu Y, Narra K, Hoehn KL, Knotts TA, Siesky A, Nelson DH, Karathanasis SK, Fontenot GK, Birnbaum MJ, Summers SA (2007) Inhibition of ceramide synthesis ameliorates glucocorticoid-, saturated-fat-, and obesity-induced insulin resistance. Cell Metab 593:167-179
86. Opara EC, Garfinkel M, Hubbard VS, Burch WM, Akwari OE (1994) Effect of fatty acids on insulin release: role of chain length and degree of unsaturation. Am J Physiol 266(4 Pt 1):E635-E639
87. Salmeron J, Hu FB, Manson JE, Stampfer MJ, Colditz GA, Rimm EB, Willett WC (2001) Dietary fat intake and risk of type 2 diabetes in women. Am J Clin Nutr 73:1019-1026 (Pubitemid 32496939)
88. Fedor D, Kelley DS (2009) Prevention of insulin resistance by n-3 polyunsaturated fatty acids. Curr Opin Clin Nutr Metab Care 12:138-146
89. Pérez-Matute P, Marti A, Martínez JA, Fernández- Otero MP, Stanhope KL, Havel PJ, Moreno-Aliaga MJ (2005) Eicosapentaenoic fatty acid increases leptin secretion from primary cultured rat adipocytes: role of glucose metabolism. Am J Physiol Regul Integr Comp Physiol 288:R1682-R1688 (Pubitemid 40720718)
90. Kalupahana NS, Claycombe K, Newman SJ, Stewart T, Siriwardhana N, Matthan N, Lichtenstein AH, Moustaid-Moussa N (2010) Eicosapentaenoic acid prevents and reverses insulin resistance in high-fat diet-induced obese mice via modulation of adipose tissue inflammation. J Nutr 140:1915-1922
91. Kraveka JM, Li L, Szulc ZM, Bielawski J, Ogretmen B, Hannun YA, Obeid LM, Bielawska A (2007) Involvement of dihydroceramide desaturase in cell cycle progression in human neuroblastoma cells. J Biol Chem 282:16718-16728 (Pubitemid 47093220)
92. Hu W, Ross JS, Geng T, Brice SE, Cowart LA (2011) Differential regulation of dihydroceramide desaturase by palmitate vs. monounsaturated fatty acids: implications to insulin resistance. J Biol Chem 285:35792-35802
93. Shmueli E, Alberti KG, Record CO (1993) Diacylglycerol/protein kinase C signalling: a mechanism for insulin resistance? J Intern Med 234:397-400 (Pubitemid 23305788)
94. Itani SI, Ruderman NB, Schmieder F, Boden G (2002) Lipidinduced insulin resistance in human muscle is associated with changes in diacylglycerol, protein kinase C, and IkappaB-alpha. Diabetes 51:2005-2011 (Pubitemid 34729001)
95. Montell E, Turini M, Marotta M, Roberts M, Noé V, Ciudad CJ, Macé K, Gómez-Foix AM (2001) DAG accumulation from saturated fatty acids desensitizes insulin stimulation of glucose uptake in muscle cells. Am J Physiol Endocrinol Metab 280:E229-E237
96. Dobbins RL, Szczepaniak LS, Bentley B, Esser V, Myhill J, McGarry JD (2001) Prolonged inhibition of muscle carnitine palmitoyltransferase-1 promotes intramyocellular lipid accumulation and insulin resistance in rats. Diabetes 50:123-130 (Pubitemid 32047990)
97. Schmitz-Peiffer C (2010) Targeting ceramide synthesis to reverse insulin resistance. Diabetes 59:2351-2353
98. Tada N (2004) Physiological actions of diacylglycerol outcome. Curr Opin Clin Nutr Metab Care 7:145-149 (Pubitemid 40340676)
99. Fujii A, Allen TJ, Nestel PJ (2007) A 1, 3-diacylglycerol-rich oil induces less atherosclerosis and lowers plasma cholesterol in diabetic apoE-deficient mice. Atherosclerosis 193:55-61 (Pubitemid 46776710)
100. Meguro S, Osaki N, Matsuo N, Tokimitsu I (2006) Effect of diacylglycerol on the development of impaired glucose tolerance in sucrose-fed rats. Lipids 41:347-355 (Pubitemid 43902263)
101. Murase T, Aoki M, Wakisaka T, Hase T, Tokimitsu I (2002) Anti-obesity effect of dietary diacylglycerol in C57BL/6J mice: dietary diacylglycerol stimulates intestinal lipid metabolism. J Lipid Res 43:1312-1319 (Pubitemid 34993532)
102. Yanai H, Tomono Y, Ito K, Furutani N, Yoshida H, Tada N (2007) Diacylglycerol oil for the metabolic syndrome. Nutr J 6:43-45
103. Holland WL, Summers SA (2008) Sphingolipids, insulin resistance, and metabolic disease: new insights from in vivo manipulation of sphingolipid metabolism. Endocr Rev 29:381-402 (Pubitemid 351831506)
104. Kitatani K, Idkowiak-Baldys J, Hannun YA (2008) The sphingolipid salvage pathway in ceramide metabolism and signaling. Cell Signal 20:1010-1018
105. Chavez JA, Knotts TA, Wang LP, Li G, Dobrowsky RT, Florant GL, Summers SA (2003) A role for ceramide, but not diacylglycerol, in the antagonism of insulin signal transduction by saturated fatty acids. J Biol Chem 278:10297-10303 (Pubitemid 36800291)
106. Summers SA (2006) Ceramides in insulin resistance and lipotoxicity. Prog Lipid Res 45:42-72 (Pubitemid 43170804)
107. Gorska M, Dobrzyn A, Zendzian-Piotrowska M, Gorski J (2004) Effect of streptozotocin-diabetes on the functioning of the sphingomyelin-signalling pathway in skeletal muscles of the rat. Horm Metab Res 36:14-21 (Pubitemid 38283188)
108. Adams JM 2nd, Pratipanawatr T, Berria R, Wang E, DeFronzo RA, Sullards MC, Mandarino LJ (2004) Ceramide content is increased in skeletal muscle from obese insulin-resistant humans. Diabetes 53:25-31 (Pubitemid 38044694)
109. Powell DJ, Hajduch E, Kular G, Hundal HS (2003) Ceramide disables 3-phosphoinositide binding to the pleckstrin homology domain of protein kinase B (PKB)/Akt by a PKCzeta-dependent mechanism. Mol Cell Biol 23:7794-7808 (Pubitemid 37271476)
110. Summers SA, Garza LA, Zhou H, Birnbaum MJ (1998) Regulation of insulin-stimulated glucose transporter GLUT4 translocation and Akt kinase activity by ceramide. Mol Cell Biol 18:5457-5464 (Pubitemid 28388128)
111. Resjo S, Goransson O, Harndahl L, Zolnierowicz S, Manganiello V, Degerman E (2002) Protein phosphatase 2A is the main phosphatase involved in the regulation of protein kinase B in rat adipocytes. Cell Signal 14:231-238 (Pubitemid 34102452)
112. Di Marzo V, Petrosino S (2007) Endocannabinoids and the regulation of their levels in health and disease. Curr Opin Lipidol 18:129-140 (Pubitemid 46412082)
113. González S, Cascio MG, Fernández-Ruiz J, Fezza F, Di Marzo V, Ramos JA (2002) Changes in endocannabinoid contents in the brain of rats chronically exposed to nicotine, ethanol or cocaine. Brain Res 954:73-81 (Pubitemid 35223443)
114. Zhang M, Martin BR, PhD AdlerMW, Razdan RK, Ganea D, Tuma RF (2008) Modulation of the balance between cannabinoid CB(1) and CB(2) receptor activation during cerebral ischemic/reperfusion injury. Neuroscience 152:753-760
115. Zhao Y, Yuan Z, Liu Y, Xue J, Tian Y, Liu W, Zhang W, Shen Y, Xu W, Liang X, Chen T (2010) Activation of cannabinoid CB2 receptor ameliorates atherosclerosis associated with suppression of adhesion molecules. J Cardiovasc Pharmacol 55:292-298
116. Di Marzo V (2008) The endocannabinoid system in obesity and type 2 diabetes. Diabetologia 51:1356-1367
117. Nogueiras R, Rohner-Jeanrenaud F, Woods SC, Tschöp MH (2008) The endocannabinoid system and the control of glucose homeostasis. J Neuroendocrinol 20(Suppl 1):147-151 (Pubitemid 351552686)
118. Micale V, Mazzola C, Drago F (2007) Endocannabinoids and neurodegenerative diseases. Pharmacol Res 56(5):382-392 (Pubitemid 350026397)
119. Mechoulam R, Spatz M, Shohami E (2002) Endocannabinoids and neuroprotection. Sci STKE 129:RE5
120. Marsicano G, Moosmann B, Hermann H, Lutz B, Behl C (2002) Neuroprotective properties of cannabinoids against oxidative stress: role of the cannabinoid receptor CB1. J Neurochem 80:448-456 (Pubitemid 36383028)
121. Fernández-Ruiz J (2009) The endocannabinoid system as a target for the treatment of motor dysfunction. Br J Pharmacol 156:1029-1040
122. Marsicano G, Goodenough S, Monory K, Hermann H, Eder M, Cannich A, Azad SC, Cascio MG, Gutiérrez SO, van der Stelt M, López-Rodriguez ML, Casanova E, Schütz G, Zieglgänsberger W, Di Marzo V, Behl C, Lutz B (2003) CB1 cannabinoid receptors and on-demand defense against excitotoxicity. Science 302:84-88 (Pubitemid 37210691)
123. Maresz K, Carrier EJ, Ponomarev ED, Hillard CJ, Dittel BN (2005) Modulation of the cannabinoid CB2 receptor in microglial cells in response to inflammatory stimuli. J Neurochem 95:437-445 (Pubitemid 41457512)
124. Esterbauer H, Schaur RJ, Zollner H (1991) Chemistry and biochemistry of 4-hydroxynonenal, malonaldehyde and related aldehydes. Free Radic Biol Med 11:81-128 (Pubitemid 121003917)
125. Mark RJ, Lovell MA, Markesbery WR, Uchida K, Mattson MP (1997) A role for 4-hydroxynonenal, an aldehydic product of lipid peroxidation, in disruption of ion homeostasis and neuronal death induced by amyloid b-peptide. J Neurochem 68:255-264 (Pubitemid 26427315)
126. Keller JN, Mattson MP (1998) Roles of lipid peroxidation in modulation of cellular signaling pathways, cell dysfunction, and death in the nervous system. Rev Neurosci 9:105-116 (Pubitemid 28386642)
127. Kadoya A, Miyake H, Ohyashiki T (2003) Contribution of lipid dynamics on the inhibition of bovine brain synaptosomal Na?-K?-ATPase activity induced by 4-hydroxy-2-nonenal. Biol Pharm Bull 26:787-793 (Pubitemid 39655296)
128. McConkey DJ (1996) The role of calcium in the regulation of apoptosis. Scanning Microsc 10:777-793
129. Xu B, Chen S, Luo Y, Chen Z, Liu L, Zhou H, Chen W, Shen T, Han X, Chen L, Huang S (2011) Calcium signaling is involved in cadmium-induced neuronal apoptosis via induction of reactive oxygen species and activation of MAPK/mTOR network PLoS One. 6:e19052
130. Keller JN, Mark RJ, Bruce AJ, Blanc E, Rothstein JD, Uchida K, Wäg G, Mattson MP (1997) 4-hydroxynonenal, an aldehydic product of membrane lipid peroxidation, impairs glutamate transport and mitochondrial function in synaptosomes. Neuroscience 80:685-696 (Pubitemid 27334614)
131. Vincent HK, Powers SK, Dirks AJ, Scarpace PJ (2001) Mechanism for obesity-induced increase in myocardial lipid peroxidation. Int J Obes Relat Metab Disord 25:378-388 (Pubitemid 32209814)
132. Russell AP, Gastaldi G, Bobbioni-Harsch E, Arboit P, Gobelet C, Dériaz O, Golay A, Witztum JL, Giacobino JP (2003) Lipid peroxidation in skeletal muscle of obese as compared to endurance-trained humans: a case of good vs. bad lipids? FEBS Lett 551:104-106 (Pubitemid 37281335)
133. Johnson JB, Summer W, Cutler RG, Martin B, Hyun DH, Dixit VD, Pearson M, Nassar M, Telljohann R, Maudsley S, Carlson O, John S, Laub DR, Mattson MP (2007) Alternate day calorie restriction improves clinical findings and reduces markers of oxidative stress and inflammation in overweight adults with moderate asthma. Free Radic Biol Med 42:665-674 (Pubitemid 46205148)
134. Grimsrud PA, Picklo MJ Sr, Griffin TJ, Bernlohr DA (2007) Carbonylation of adipose proteins in obesity and insulin resistance: identification of adipocyte fatty acid-binding protein as a cellular target of 4-hydroxynonenal. Mol Cell Proteomics 6:624-637 (Pubitemid 46630095)
135. Zarrouki B, Soares AF, Guichardant M, Lagarde M, Géloën A (2007) The lipid peroxidation end-product 4-HNE induces COX-2 expression through p38MAPK activation in 3T3-L1 adipose cell. FEBS Lett 581:2394-2400 (Pubitemid 46764695)
136. Mattson MP (2009) Roles of the lipid peroxidation product 4-hydroxynonenal in obesity, the metabolic syndrome, and associated vascular and neurodegenerative disorders. Exp Gerontol 44:625-633
137. Singh SP, Niemczyk M, Saini D, Awasthi YC, Zimniak L, Zimniak P (2008) Role of the electrophilic lipid peroxidation product 4-hydroxynonenal in the development and maintenance of obesity in mice. Biochemistry 47:3900-3911 (Pubitemid 351431379)
138. Devaraj S, Wang-Polagruto J, Polagruto J, Keen CL, Jialal I (2008) High-fat, energy-dense, fast-food-style breakfast results in an increase in oxidative stress in metabolic syndrome. Metabolism 57:867-870 (Pubitemid 351697920)
139. Murakami H, Tamasawa N, Matsui J, Yamato K, JingZhi G, Suda T (2001) Plasma levels of soluble vascular adhesion molecule-1 and cholesterol oxidation product in type 2 diabetic patients with nephropathy. J Atheroscler Thromb 8:21-24
140. Krook A (2006) Can the liver X receptor work its magic in skeletal muscle too? Diabetologia 49:819-821
141. Knopp RH, Paramsothy P (2006) Oxidized LDL and abdominal obesity: a key to understanding the metabolic syndrome. Am J Clin Nutr 83:1-2 (Pubitemid 44699225)
142. Ivanova PT, Milne SB, Forrester JS, Brown HA (2004) LIPID arrays: new tools in the understanding of membrane dynamics and lipid signaling. Mol Interv 4:86-96 (Pubitemid 38584971)
143. Prineas RJ, Folsom AR, Kaye SA (1993) Central adiposity and increased risk of coronary artery disease mortality in older women. Ann Epidemiol 3:35-41 (Pubitemid 23050727)
144. Kip KE, Morroguin OC, Kelley DE, Johnson BP, Kelsey SF, Shaw LJ, Rogers WJ, Reis SE (2004) Clinical importance of obesity versus the metabolic syndrome in cardiovascular risk in women: a report from the Women's Ischemia Syndrome Evaluation (WISE) study. Circulation 109:706-713 (Pubitemid 38222888)
145. Chien KL, Hsu HC, Sung FC, Su TC, Chen MF, Lee YT (2007) Metabolic syndrome as a risk factor for coronary heart disease and stroke: an 11-year prospective cohort in Taiwan community. Atherosclerosis 194:214-221
146. Gazdzinski S, Kornak J, Weiner MW, Meyerhoff DJ (2008) Body mass index and magnetic resonance markers of brain integrity in adults. Ann Neurol 63:652-657
147. Lusis AJ, Attie AD, Reue K (2008) Metabolic syndrome: from epidemiology to systems biology. Nat Rev Genet 9:819-830
148. Kawamoto R, Tomita H, Oka Y, Kodama A (2005) Metabolic syndrome as a predictor of ischemic stroke in elderly persons. Intern Med 44:922-927 (Pubitemid 41644088)
149. Scott CL (2003) Diagnosis, prevention, and intervention for the metabolic syndrome. Am J Cardiol 92:35i-42i (Pubitemid 36831113)
150. McNeill A, Rosamond W, Girman C, Golden S, Schmidt MI, East H, Ballantyne C, Heiss G (2005) The metabolic syndrome and 11-year risk of incident cardiovascular disease in the Atherosclerosis Risk in Communities Study. Diabetes Care 28:385-390 (Pubitemid 40170944)
151. Wannamethee SG, Shaper AG, Lennon L, Morris RW (2005) Metabolic syndrome vs Framingham Risk Score for prediction of coronary heart disease, stroke, and type 2 diabetes mellitus. Arch Intern Med 165:2644-2650 (Pubitemid 41785063)
152. Boden-Albala B, Sacco RL, Lee HS, Grahame-Clarke C, Rundek T, Elkind MV, Wright C, Giardina EG, DiTullio MR, Homma S, Paik MC (2008) Metabolic syndrome and ischemic stroke risk: Northern Manhattan Study. Stroke 39:30-35
153. Farooqui AA (2010) Neurochemical aspects of neurotraumatic and neurodegenerative diseases. Springer, New York
154. Maejima K, Nakano S, Himeno M, Tsuda S, Makiishi H, Ito T, Nakagawa A, Kigoshi T, Ishibashi T, Nishio M, Uchida K (2001) Increased basal levels of plasma nitric oxide in type 2 diabetic subjects: relationship to microvascular complications. J Diabetes Complications 15:135-143 (Pubitemid 32453170)
155. Cosentino F, Rubattu S, Savoia C, Venturelli V, Pagannonne E, Volpe M (2001) Endothelial dysfunction and stroke. J Cardiovasc Pharmacol 38(Suppl 2):S75-S78 (Pubitemid 34020562)
156. Nazir FS, Alem M, Small M, Connell JM, Lees KR, Walters MR, Cleland SJ (2006) Blunted response to systemic nitric oxide synthase inhibition in the cerebral circulation of patients with type 2 diabetes. Diabet Med 23:398-402
157. Aoki I, Shimoyama K, Aoki N, Homori M, Yanagisawa A, Nakahara K, Kawai Y, Kitamura SI, Ishikawa K (1996) Plateletdependent thrombin generation in patients with diabetes mellitus: effects of glycemic control on coagulability in diabetes. J Am Coll Cardiol 27:560-566
158. Davi G, Gennaro F, Spatola A, Catalano I, Averna M, Montalto G, Amato S, Notarbartolo A (1992) Thrombin-antithrombin III complexes in type II diabetes mellitus. J Diabetes Complicat 6:7-11 (Pubitemid 23034744)
159. Romano M, Guagnano MT, Pacini G, Vigneri S, Falco A, Marinopiccoli M, Manigrasso MR, Basili S, Davi G (2003) Association of inflammation markers with impaired insulin sensitivity and coagulative activation in obese healthy women. J Clin Endocrinol Metab 88:5321-5326 (Pubitemid 37452734)
160. Ballantyne CM, Hoogeveen RC, Bang H, Coresh J, Folsom AR, Chambless LE, Myerson M, Wu KK, Sharrett AR, Boerwinkle E (2005) Lipoprotein-associated phospholipase A2, high-sensitivity C-reactive protein, and risk for incident ischemic stroke in middle-aged men and women in the Atherosclerosis Risk in Communities (ARIC) study. Arch Intern Med 165:2479-2484 (Pubitemid 41720009)
161. Engstrom G, Stavenow L, Hedblad B, Lind P, Eriksson KF, Janzon L, Lindgarde F (2003) Inflammation-sensitive plasma proteins, diabetes, and mortality and incidence of myocardial infarction and stroke: a population-based study. Diabetes 52:442-447 (Pubitemid 36173201)
162. Trovati M, Mularoni EM, Burzacca S, Ponziani MC, Massucco P, Mattiello L, Piretto V, Cavalot F, Anfossi G (1995) Impaired insulin-induced platelet antiaggregating effect in obesity and in obese NIDDM patients. Diabetes 44:1318-1322
163. Wagenknecht LE, D'Agostino R Jr, Savage PJ, O'Leary DH, Saad MF, Haffner SM (1997) Duration of diabetes and carotid wall thickness: the Insulin Resistance Atherosclerosis Study (IRAS). Stroke 28:999-1005 (Pubitemid 27209149)
164. Biessels GJ, Kappelle LJ (2005) Increased risk of Alzheimer's disease in Type II diabetes: insulin resistance of the brain or insulin-induced amyloid pathology? Biochem Soc Trans 33:1041-1044 (Pubitemid 41659109)
165. Luchsinger JA, Tang MX, Shea S, Mayeux R (2004) Hyperinsulinemia and risk of Alzheimer disease. Neurology 63:1187-1192 (Pubitemid 39350015)
166. Gasparini L, Gouras GK, Wang R, Gross RS, Beal MF, Greengard P, Xu H (2001) Stimulation of betaamyloid precursor protein trafficking by insulin reduces intraneuronal beta-amyloid and requires mitogen-activated protein kinase signaling. J Neurosci 21:2561-2570 (Pubitemid 32298198)
167. Perez A, Morell L, Cresto JC, Castano EM (2000) Degradation of soluble amyloid beta-peptides 1-40, 1-42, and the Dutch variant 1-40Q by insulin degrading enzyme from Alzheimer disease and control brains. Neurochem Res 25:247-255 (Pubitemid 30210091)
168. Tamagno E, Parola M, Bardini P, Piccini A, Borghi R, Guglielmotto M, Santoro G, Davit A, Danni O, Smith MA, Perry G, Tabaton M (2005) Beta-site APP cleaving enzyme up-regulation induced by 4-hydroxynonenal is mediated by stress-activated protein kinases pathways. J Neurochem 92:628-636 (Pubitemid 40189465)
169. Sun MK, Alkon DL (2006) Links between Alzheimer's disease and diabetes. Drugs Today (Barc) 42:481-489 (Pubitemid 44221017)
170. Grossman H (2003) Does diabetes protect or provoke Alzheimer's disease? Insights into the pathobiology and future treatment of Alzheimer's disease. CNS Spectr 8:815-823
171. Craft S, Reger MA, Baker LD (2006) Insulin resistance in Alzheimer's diseasë. Alzheimer's disease and related disorders Annual 5. Taylor and Francis, London, pp 111-133
172. Revill P, Moral M, Prous JR (2006) Impaired insulin signaling and the pathogenesis of Alzheimer's disease. Drug Today 42:785-790
173. Whitmer RA (2007) Type 2 diabetes and risk of cognitive impairment and dementia. Curr Neurol Neurosci Rep 7:373-380 (Pubitemid 47422778)
174. van Reedt Dortland AK, Giltay EJ, van Veen T, Zitman FG, Penninx BW (2010) Metabolic syndrome abnormalities are associated with severity of anxiety and depression and with tricyclic antidepressant use. Acta Psychiatr Scand 122:30-39
175. McIntyre RS, Park KY, Law CW, Sultan F, Adams A, Lourenco MT, Lo AK, Soczynska JK, Woldeyohannes H, Alsuwaidan M, Yoon J, Kennedy SH (2010) The association between conventional antidepressants and the metabolic syndrome: a review of the evidence and clinical implications. CNS Drugs 24:741-753
176. Wurtman RJ (2005) Genes, stress, and depression. Metabolism 54(5 Suppl 1):16-19 (Pubitemid 40546017)
177. Brummett BH, Boyle SH, Siegler IC, Kuhn CM, Ashley-Koch A, Jonassaint CR, Züchner S, Collins A, Williams RB (2008) Effects of environmental stress and gender on associations among symptoms of depression and the serotonin transporter gene linked polymorphic region (5-HTTLPR). Behav Genet 38:34-43 (Pubitemid 351164912)
178. Leonard BE, Myint A (2009) The psychoneuroimmunology of depression. Hum Psychopharmacol 24:165-175
179. Anisman H (2009) Cascading effects of stressors and inflammatory immune system activation: implications for major depressive disorder. J Psychiatry Neurosci 34:4-20
180. Swaab DF, Bao AM, Lucassen PJ (2005) The stress system in the human brain in depression and neurodegeneration. Ageing Res Rev 4:141-194 (Pubitemid 41114861)
181. Chesik D, Wilczak N, De Keyser J (2008) IGF-1 regulates cAMP levels in astrocytes through a beta2-adrenergic receptordependant mechanism. Int J Med Sci 5:240-243
182. Robertson SD, Matthies HJ, Owens WA, Sathananthan V, Christianson NS, Kennedy JP, Lindsley CW, Daws LC, Galli A (2010) Insulin reveals Akt signaling as a novel regulator of norepinephrine transporter trafficking and norepinephrine homeostasis. J Neurosci 30:11305-11316
183. Frisardi V, Panza F, Farooqui AA (2011) Late-life depression and Alzheimer's disease: the glutamatergic system inside of this mirror relationship. Brain Res Rev 67:344-355
184. Bardgett ME, McCarthy JJ, Stocker SD (2010) Glutamatergic receptor activation in the rostral ventrolateral medulla mediates the sympathoexcitatory response to hyperinsulinemia. Hypertension 55:284-290
185. Biancardi VC, Campos RR, Stern JE (2010) Altered balance of gamma-aminobutyric acidergic and glutamatergic afferent inputs in rostral ventrolateral medulla-projecting neurons in the paraventricular nucleus of the hypothalamus of renovascular hypertensive rats. J Comp Neurol 518:567-585
186. Novgorodtseva TP, Karaman YK, Zhukova NV, Lobanova EG, Antonyuk MV, Kantur TA (2011) Composition of fatty acids in plasma and erythrocytes and eicosanoids level in patients with metabolic syndrome. Lipids Health Dis 10:82
187. Henkel J, Gärtner D, Dorn C, Hellerbrand C, Schanze N, Elz SR, Püschel GP (2011) Oncostatin M produced in Kupffer cells in response to PGE2: possible contributor to hepatic insulin resistance and steatosis. Lab Invest 91:1107-1117
188. McLarnon JG, Choi HB, Lue LF, Walker DG, Kim SU (2005) Perturbations in calcium-mediated signal transduction in microglia from Alzheimer's disease patients. J Neurosci Res 81:426-435 (Pubitemid 41359297)
189. Derbent A, Kargili A, Koca C, Gümüş II?, Sevgili S, Simavli S, Karakurt F, Turhan NÖ (2011) Serum platelet-activating factor acetylhydrolase activity: relationship with metabolic syndrome in women with history of gestational diabetes mellitus. Gynecol Endocrinol 27:128-133
190. Holland WL, Knotts TA, Chavez JA, Wang LP, Hoehn KL, Summers SA (2007) Lipid mediators of insulin resistance. Nutr Rev 65:S39-S46
191. Alkazemi D, Egeland G, Vaya J, Meltzer S, Kubow S (2008) Oxysterol as a marker of atherogenic dyslipidemia in adolescence. J Clin Endocrinol Metab 93:4282-4289 (Pubitemid 352789523)